Ayush Ministry orders Patanjali to stop advertising ‘Coronil’ without verification

On the basis of media report, The Union Ministry of AYUSH has come forward on Ayurvedic medicines developed by Patanjali Ayurved Ltd. for treatment of Covid-19.

A clarification has been released by The Ministry that facts claiming treatment of Covid-19 and details of the stated scientific study are not known to it and ministry has therefore asked the company to stop advertising such claims.

The Ministry has also asked the company ‘Patanjali’ not to advertise from making such claims without verification from concerned authorities.

The Ministry has also said in the starement that Ayurvedic medicines, are regulated under the provisions of Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and Rules thereunder.

Furthermore, Ministry has also requested concerned State Licensing Authority of Uttrakhand Government to provide copies of license and product approval details of the Ayurvedic medicines being claimed for the treatment of COVID -19.

The Government has asked Patanjali Ayurved to disclose the name and composition of the medicines being claimed for COVID treatment;
site(s)/hospital(s), the place where research study was conducted for COVID-19;
protocol, sample size, Institutional Ethics Committee clearance, CTRI registration and results data of the study(ies).
Earlier, Ministry had issued a Gazette Notification on April 21, 2020, stipulating all the requirements and the manner in which the research studies on COVID-19 have to be undertaken, with Ayush interventions/medicines.

The AYUSH Ministry had permitted clinical trials of four ayurvedic medicines for the treatment of the disease.

Related Posts

Excellence of Accredited Hospitals to be judged on how Friendly they are with Patients

Patients for Patient Safety Foundation (PFPSF) Partners with CAHO to RollOut an Excellence Program New Delhi: Thanks to some well-meaning organizations, patients are going to be lord of all they…

How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

BMJ Research Forum all set to mull over in Delhi on September 5 New Delhi: Research in healthcare in India is a dime a dozen. But the real question that…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

FDA seizes food stock worth Rs 63.45 crore, suspends 954 licences in two months

FDA seizes food stock worth Rs 63.45 crore, suspends 954 licences in two months

Stents to syringes: Serious harm reports surge, but makers remain unnamed

Stents to syringes: Serious harm reports surge, but makers remain unnamed

NPPA Revises Retail and Ceiling Prices of 35 Drug Formulations; Fixes Prices of 34 New Drugs, Cholecalciferol, Oxaliplatin and Sun Pharma’s Diclofenac Gel

NPPA Revises Retail and Ceiling Prices of 35 Drug Formulations; Fixes Prices of 34 New Drugs, Cholecalciferol, Oxaliplatin and Sun Pharma’s Diclofenac Gel

ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

Hyderabad Startup Working On Personalised Cancer Vaccine: What It Means For Cancer Treatment

Hyderabad Startup Working On Personalised Cancer Vaccine: What It Means For Cancer Treatment

Medicines that cure Us are making Our Environment Sick

Medicines that cure Us are making Our Environment Sick